Selected research
Industry Research
Microarray-based Non-Invasive Prenatal Testing Industry Research Report 2026
Market perspective
The global Microarray-based Non-Invasive Prenatal Testing market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Microarray-based Non-Invasive Prenatal Testing market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Microarray-based Non-Invasive Prenatal Testing market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Microarray-based Non-Invasive Prenatal Testing market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Microarray-based Non-Invasive Prenatal Testing include Agilent Technologies, Ariosa Diagnostics (Roche), BGI Group, Eurofins LifeCodexx GmbH, Illumina, Laboratory Corporation of America, Myriad Genetics, Natera and PerkinElmer Inc, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Microarray-based Non-Invasive Prenatal Testing market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Microarray-based Non-Invasive Prenatal Testing.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Microarray-based Non-Invasive Prenatal Testing Market by Company
Agilent Technologies
Ariosa Diagnostics (Roche)
BGI Group
Eurofins LifeCodexx GmbH
Illumina
Laboratory Corporation of America
Myriad Genetics
Natera
PerkinElmer Inc
Quest Diagnostics
Sequenom
Microarray-based Non-Invasive Prenatal Testing Segment by Type
Trisomy Detection
Microdeletion Syndromes
Other
Microarray-based Non-Invasive Prenatal Testing Segment by Application
Hospitals & Clinics
Independent Laboratories
Microarray-based Non-Invasive Prenatal Testing Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Microarray-based Non-Invasive Prenatal Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Microarray-based Non-Invasive Prenatal Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Microarray-based Non-Invasive Prenatal Testing.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Microarray-based Non-Invasive Prenatal Testing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Trisomy Detection
- Microdeletion Syndromes
- Other
Applications
- Hospitals & Clinics
- Independent Laboratories
Companies covered
- Agilent Technologies
- Ariosa Diagnostics (Roche)
- BGI Group
- Eurofins LifeCodexx GmbH
- Illumina
- Laboratory Corporation of America
- Myriad Genetics
- Natera
- PerkinElmer Inc
- Quest Diagnostics
- Sequenom
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Microarray-based Non-Invasive Prenatal Testing by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Trisomy Detection
- 2.2.3 Microdeletion Syndromes
- 2.2.4 Other
- 2.3 Microarray-based Non-Invasive Prenatal Testing by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospitals & Clinics
- 2.3.3 Independent Laboratories
- 2.4 Assumptions and Limitations
3 Microarray-based Non-Invasive Prenatal Testing Breakdown Data by Type
- 3.1 Global Microarray-based Non-Invasive Prenatal Testing Historic Market Size by Type (2021-2026)
- 3.2 Global Microarray-based Non-Invasive Prenatal Testing Forecasted Market Size by Type (2027-2032)
4 Microarray-based Non-Invasive Prenatal Testing Breakdown Data by Application
- 4.1 Global Microarray-based Non-Invasive Prenatal Testing Historic Market Size by Application (2021-2026)
- 4.2 Global Microarray-based Non-Invasive Prenatal Testing Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Microarray-based Non-Invasive Prenatal Testing Market Perspective (2021-2032)
- 5.2 Global Microarray-based Non-Invasive Prenatal Testing Growth Trends by Region
- 5.2.1 Global Microarray-based Non-Invasive Prenatal Testing Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Microarray-based Non-Invasive Prenatal Testing Historic Market Size by Region (2021-2026)
- 5.2.3 Microarray-based Non-Invasive Prenatal Testing Forecasted Market Size by Region (2027-2032)
- 5.3 Microarray-based Non-Invasive Prenatal Testing Market Dynamics
- 5.3.1 Microarray-based Non-Invasive Prenatal Testing Industry Trends
- 5.3.2 Microarray-based Non-Invasive Prenatal Testing Market Drivers
- 5.3.3 Microarray-based Non-Invasive Prenatal Testing Market Challenges
- 5.3.4 Microarray-based Non-Invasive Prenatal Testing Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Microarray-based Non-Invasive Prenatal Testing Players by Revenue
- 6.1.1 Global Top Microarray-based Non-Invasive Prenatal Testing Players by Revenue (2021-2026)
- 6.1.2 Global Microarray-based Non-Invasive Prenatal Testing Revenue Market Share by Players (2021-2026)
- 6.2 Global Microarray-based Non-Invasive Prenatal Testing Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Microarray-based Non-Invasive Prenatal Testing Head Office and Area Served
- 6.4 Global Microarray-based Non-Invasive Prenatal Testing Players, Product Type & Application
- 6.5 Global Microarray-based Non-Invasive Prenatal Testing Manufacturers Established Date
- 6.6 Global Microarray-based Non-Invasive Prenatal Testing Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Microarray-based Non-Invasive Prenatal Testing Market Size (2021-2032)
- 7.2 North America Microarray-based Non-Invasive Prenatal Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Microarray-based Non-Invasive Prenatal Testing Market Size by Country (2021-2026)
- 7.4 North America Microarray-based Non-Invasive Prenatal Testing Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Microarray-based Non-Invasive Prenatal Testing Market Size (2021-2032)
- 8.2 Europe Microarray-based Non-Invasive Prenatal Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Microarray-based Non-Invasive Prenatal Testing Market Size by Country (2021-2026)
- 8.4 Europe Microarray-based Non-Invasive Prenatal Testing Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Microarray-based Non-Invasive Prenatal Testing Market Size (2021-2032)
- 9.2 Asia-Pacific Microarray-based Non-Invasive Prenatal Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Microarray-based Non-Invasive Prenatal Testing Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Microarray-based Non-Invasive Prenatal Testing Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Microarray-based Non-Invasive Prenatal Testing Market Size (2021-2032)
- 10.2 South America Microarray-based Non-Invasive Prenatal Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Microarray-based Non-Invasive Prenatal Testing Market Size by Country (2021-2026)
- 10.4 South America Microarray-based Non-Invasive Prenatal Testing Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Microarray-based Non-Invasive Prenatal Testing Market Size (2021-2032)
- 11.2 Middle East & Africa Microarray-based Non-Invasive Prenatal Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Microarray-based Non-Invasive Prenatal Testing Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Microarray-based Non-Invasive Prenatal Testing Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Agilent Technologies
- 12.1.1 Agilent Technologies Company Information
- 12.1.2 Agilent Technologies Business Overview
- 12.1.3 Agilent Technologies Revenue in Microarray-based Non-Invasive Prenatal Testing Business (2021-2026)
- 12.1.4 Agilent Technologies Microarray-based Non-Invasive Prenatal Testing Product Portfolio
- 12.1.5 Agilent Technologies Recent Developments
- 12.2 Ariosa Diagnostics (Roche)
- 12.2.1 Ariosa Diagnostics (Roche) Company Information
- 12.2.2 Ariosa Diagnostics (Roche) Business Overview
- 12.2.3 Ariosa Diagnostics (Roche) Revenue in Microarray-based Non-Invasive Prenatal Testing Business (2021-2026)
- 12.2.4 Ariosa Diagnostics (Roche) Microarray-based Non-Invasive Prenatal Testing Product Portfolio
- 12.2.5 Ariosa Diagnostics (Roche) Recent Developments
- 12.3 BGI Group
- 12.3.1 BGI Group Company Information
- 12.3.2 BGI Group Business Overview
- 12.3.3 BGI Group Revenue in Microarray-based Non-Invasive Prenatal Testing Business (2021-2026)
- 12.3.4 BGI Group Microarray-based Non-Invasive Prenatal Testing Product Portfolio
- 12.3.5 BGI Group Recent Developments
- 12.4 Eurofins LifeCodexx GmbH
- 12.4.1 Eurofins LifeCodexx GmbH Company Information
- 12.4.2 Eurofins LifeCodexx GmbH Business Overview
- 12.4.3 Eurofins LifeCodexx GmbH Revenue in Microarray-based Non-Invasive Prenatal Testing Business (2021-2026)
- 12.4.4 Eurofins LifeCodexx GmbH Microarray-based Non-Invasive Prenatal Testing Product Portfolio
- 12.4.5 Eurofins LifeCodexx GmbH Recent Developments
- 12.5 Illumina
- 12.5.1 Illumina Company Information
- 12.5.2 Illumina Business Overview
- 12.5.3 Illumina Revenue in Microarray-based Non-Invasive Prenatal Testing Business (2021-2026)
- 12.5.4 Illumina Microarray-based Non-Invasive Prenatal Testing Product Portfolio
- 12.5.5 Illumina Recent Developments
- 12.6 Laboratory Corporation of America
- 12.6.1 Laboratory Corporation of America Company Information
- 12.6.2 Laboratory Corporation of America Business Overview
- 12.6.3 Laboratory Corporation of America Revenue in Microarray-based Non-Invasive Prenatal Testing Business (2021-2026)
- 12.6.4 Laboratory Corporation of America Microarray-based Non-Invasive Prenatal Testing Product Portfolio
- 12.6.5 Laboratory Corporation of America Recent Developments
- 12.7 Myriad Genetics
- 12.7.1 Myriad Genetics Company Information
- 12.7.2 Myriad Genetics Business Overview
- 12.7.3 Myriad Genetics Revenue in Microarray-based Non-Invasive Prenatal Testing Business (2021-2026)
- 12.7.4 Myriad Genetics Microarray-based Non-Invasive Prenatal Testing Product Portfolio
- 12.7.5 Myriad Genetics Recent Developments
- 12.8 Natera
- 12.8.1 Natera Company Information
- 12.8.2 Natera Business Overview
- 12.8.3 Natera Revenue in Microarray-based Non-Invasive Prenatal Testing Business (2021-2026)
- 12.8.4 Natera Microarray-based Non-Invasive Prenatal Testing Product Portfolio
- 12.8.5 Natera Recent Developments
- 12.9 PerkinElmer Inc
- 12.9.1 PerkinElmer Inc Company Information
- 12.9.2 PerkinElmer Inc Business Overview
- 12.9.3 PerkinElmer Inc Revenue in Microarray-based Non-Invasive Prenatal Testing Business (2021-2026)
- 12.9.4 PerkinElmer Inc Microarray-based Non-Invasive Prenatal Testing Product Portfolio
- 12.9.5 PerkinElmer Inc Recent Developments
- 12.10 Quest Diagnostics
- 12.10.1 Quest Diagnostics Company Information
- 12.10.2 Quest Diagnostics Business Overview
- 12.10.3 Quest Diagnostics Revenue in Microarray-based Non-Invasive Prenatal Testing Business (2021-2026)
- 12.10.4 Quest Diagnostics Microarray-based Non-Invasive Prenatal Testing Product Portfolio
- 12.10.5 Quest Diagnostics Recent Developments
- 12.11 Sequenom
- 12.11.1 Sequenom Company Information
- 12.11.2 Sequenom Business Overview
- 12.11.3 Sequenom Revenue in Microarray-based Non-Invasive Prenatal Testing Business (2021-2026)
- 12.11.4 Sequenom Microarray-based Non-Invasive Prenatal Testing Product Portfolio
- 12.11.5 Sequenom Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst